SG11201907084VA - Pharmaceutical compositions for combination therapy - Google Patents
Pharmaceutical compositions for combination therapyInfo
- Publication number
- SG11201907084VA SG11201907084VA SG11201907084VA SG11201907084VA SG11201907084VA SG 11201907084V A SG11201907084V A SG 11201907084VA SG 11201907084V A SG11201907084V A SG 11201907084VA SG 11201907084V A SG11201907084V A SG 11201907084VA SG 11201907084V A SG11201907084V A SG 11201907084VA
- Authority
- SG
- Singapore
- Prior art keywords
- international
- loos
- pct
- danel
- leonard
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
- A61K31/19—Carboxylic acids, e.g. valproic acid
- A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
Landscapes
- Health & Medical Sciences (AREA)
- Public Health (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Gastroenterology & Hepatology (AREA)
- Pain & Pain Management (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Plant Substances (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Enzymes And Modification Thereof (AREA)
- Peptides Or Proteins (AREA)
Abstract
WO 18/ 15408 1 Al (12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT) (19) World Intellectual Property Organization International Bureau (43) International Publication Date 30 August 2018 (30.08.2018) WIP0 I PCT ill mu °mons °nolo OH 100 Ho oinio oimIE (10) International Publication Number WO 2018/154081 Al (51) International Patent Classification: A61K 31/41 78 (2006.01) A61K 31/192 (2006.01) A61K 45/06 (2006.01) (21) International Application Number: PCT/EP2018/054588 (22) International Filing Date: 23 February 2018 (23.02.2018) (25) Filing Language: English (26) Publication Language: English (30) Priority Data: 17305213.5 24 February 2017 (24.02.2017) EP (71) Applicant: GENFIT [FR/FR]; 885 avenue Eugene Avinee, 59120 LOOS (FR). (72) Inventors: DESCAMPS, Emeline; 9 me Leonard Danel, 59120 LOOS (FR). WALCZAK, Robert; Residence Parc d'Isly, 13B me Delezenne, 59000 LILLE (FR). BE- LANGER, Carole; 3 Allee du Verger, 59910 BONDUES (FR). NOEL, Benoit; 9 me Leonard Danel, 59120 Loos (FR). (74) Agent: CABINET BECKER ET ASSOCIES; 25, rue Louis le Grand, 75002 PARIS (FR). (81) Designated States (unless otherwise indicated, for every kind of national protection available): AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JO, JP, KE, KG, KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW. (84) Designated States (unless otherwise indicated, for every kind of regional protection available): ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, ST, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG). Published: with international search report (Art. 21(3)) with sequence listing part of description (Rule 5.2(a)) (54) Title: PHARMACEUTICAL COMPOSITIONS FOR COMBINATION THERAPY (57) : The present invention relates to a combination of active ingredients for use in the treatment of diseases.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP17305213 | 2017-02-24 | ||
| PCT/EP2018/054588 WO2018154081A1 (en) | 2017-02-24 | 2018-02-23 | Pharmaceutical compositions for combination therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| SG11201907084VA true SG11201907084VA (en) | 2019-09-27 |
Family
ID=58231557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| SG11201907084VA SG11201907084VA (en) | 2017-02-24 | 2018-02-23 | Pharmaceutical compositions for combination therapy |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US11590108B2 (en) |
| EP (1) | EP3585384A1 (en) |
| JP (1) | JP2020510651A (en) |
| KR (1) | KR102633249B1 (en) |
| CN (1) | CN110418641A (en) |
| AU (1) | AU2018223976B2 (en) |
| BR (1) | BR112019017314A2 (en) |
| CA (1) | CA3051977A1 (en) |
| EA (1) | EA201991990A1 (en) |
| IL (1) | IL268708B (en) |
| MX (1) | MX2019009909A (en) |
| PH (1) | PH12019501820A1 (en) |
| SG (1) | SG11201907084VA (en) |
| WO (1) | WO2018154081A1 (en) |
| ZA (1) | ZA201906153B (en) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3435996B1 (en) * | 2016-03-31 | 2025-04-30 | Genfit | Elafibranor for use in the treatment of primary biliary cholangitis |
| US12053445B2 (en) | 2016-03-31 | 2024-08-06 | Genfit | Methods of treatment of cholestatic diseases |
Family Cites Families (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2459172C (en) | 2001-08-08 | 2011-07-05 | Takeda Chemical Industries, Ltd. | Bicyclic compound, production and use thereof |
| FR2841900B1 (en) | 2002-07-08 | 2007-03-02 | Genfit S A | NOVEL SUBSTITUTED 1,3-DIPHENYLPROP-2-EN-1-ONE DERIVATIVES, PREPARATION AND USES |
| BR112012012815B8 (en) * | 2009-11-26 | 2021-05-25 | Genfit | use of a compound selected from 1-[4-methyl-thio-phenyl]-3-[3,5-dimethyl-4-carboxy-dimethyl-methyloxy-phenyl]prop-2-en-1-one and 2-acid [2,6-dimethyl-4-[3-[4-(methyl-thio)phenyl]-3-oxo-propyl]phenoxy]-2-methylpropanoic |
| PT2771003T (en) * | 2011-10-28 | 2017-07-26 | Lumena Pharmaceuticals Llc | Bile acid recycling inhibitors for treatment of pediatric cholestatic liver diseases |
| RU2724339C2 (en) * | 2014-03-21 | 2020-06-23 | Тобира Терапьютикс, Инк. | Cenicriviroc for treating fibrosis |
| KR20170066418A (en) | 2014-09-12 | 2017-06-14 | 토비라 쎄라퓨틱스, 인크. | Cenicriviroc combination therapy for the treatment of fibrosis |
| AU2016323468A1 (en) | 2015-09-16 | 2018-04-26 | Tobira Therapeutics, Inc. | Cenicriviroc combination therapy for the treatment of fibrosis |
| EP3435996B1 (en) * | 2016-03-31 | 2025-04-30 | Genfit | Elafibranor for use in the treatment of primary biliary cholangitis |
| CN109152760B (en) * | 2016-04-11 | 2022-09-23 | 基恩菲特公司 | Methods of treating cholestatic and fibrotic diseases |
| JOP20190040A1 (en) * | 2016-09-14 | 2019-03-10 | Novartis Ag | Combination of fxr agonists |
| CA3046158A1 (en) * | 2017-01-27 | 2018-08-02 | Genfit | Pharmaceutical compositions for combination therapy |
-
2018
- 2018-02-23 SG SG11201907084VA patent/SG11201907084VA/en unknown
- 2018-02-23 CA CA3051977A patent/CA3051977A1/en active Pending
- 2018-02-23 MX MX2019009909A patent/MX2019009909A/en unknown
- 2018-02-23 EA EA201991990A patent/EA201991990A1/en unknown
- 2018-02-23 KR KR1020197027007A patent/KR102633249B1/en active Active
- 2018-02-23 BR BR112019017314A patent/BR112019017314A2/en not_active Application Discontinuation
- 2018-02-23 WO PCT/EP2018/054588 patent/WO2018154081A1/en not_active Ceased
- 2018-02-23 JP JP2019546127A patent/JP2020510651A/en active Pending
- 2018-02-23 CN CN201880013686.4A patent/CN110418641A/en active Pending
- 2018-02-23 US US16/485,025 patent/US11590108B2/en active Active
- 2018-02-23 EP EP18705945.6A patent/EP3585384A1/en not_active Withdrawn
- 2018-02-23 AU AU2018223976A patent/AU2018223976B2/en active Active
-
2019
- 2019-08-06 PH PH12019501820A patent/PH12019501820A1/en unknown
- 2019-08-14 IL IL268708A patent/IL268708B/en unknown
- 2019-09-18 ZA ZA2019/06153A patent/ZA201906153B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| MX2019009909A (en) | 2019-10-14 |
| PH12019501820A1 (en) | 2020-09-14 |
| IL268708A (en) | 2019-10-31 |
| BR112019017314A2 (en) | 2020-04-14 |
| KR20190119097A (en) | 2019-10-21 |
| AU2018223976A1 (en) | 2019-09-05 |
| ZA201906153B (en) | 2024-10-30 |
| EA201991990A1 (en) | 2020-04-07 |
| US20190388394A1 (en) | 2019-12-26 |
| US11590108B2 (en) | 2023-02-28 |
| CA3051977A1 (en) | 2018-08-30 |
| NZ756338A (en) | 2025-06-27 |
| IL268708B (en) | 2022-05-01 |
| WO2018154081A1 (en) | 2018-08-30 |
| JP2020510651A (en) | 2020-04-09 |
| AU2018223976B2 (en) | 2023-08-17 |
| KR102633249B1 (en) | 2024-02-02 |
| CN110418641A (en) | 2019-11-05 |
| EP3585384A1 (en) | 2020-01-01 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| SG11201907673YA (en) | Pharmaceutical compositions for combination therapy | |
| SG11201906041QA (en) | Pharmaceutical compositions for combination therapy | |
| SG11201906987RA (en) | Combination of a ppar agonist with a fxr agonist | |
| SG11201909168VA (en) | Combination comprising a ppar agonist such as elafibranor and an acetyl-coa carboxylase (acc) inhibitor | |
| SG11201907034PA (en) | Methods of treating influenza | |
| SG11201808222RA (en) | Methods of treatment of cholestatic diseases | |
| SG11201901390TA (en) | Tetracycline compounds and methods of treatment | |
| SG11201806868TA (en) | Compositions and methods for protecting against airborne pathogens and irritants | |
| SG11201909960UA (en) | Methods for improving memory and cognition and for treating memory and cognitive disorders | |
| SG11201810579YA (en) | Pyrimidin-2-ylamino-1h-pyrazols as lrrk2 inhibitors for use in the treatment of neurodegenerative disorders | |
| SG11201810280YA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201901534VA (en) | Combination therapy with controlled-release cnp agonists | |
| SG11201808106YA (en) | Use of masitinib for treatment of an amyotrophic lateral sclerosis patient subpopulation | |
| SG11201907804QA (en) | Pharmaceutical composition comprising selexipag | |
| SG11201900551WA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900546UA (en) | Spiro-lactam and bis-spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900554YA (en) | Spiro-lactam nmda modulators and methods of using same | |
| SG11201900558RA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201900443VA (en) | Spiro-lactam nmda receptor modulators and uses thereof | |
| SG11201906436VA (en) | Novel heterocyclic compound, its preparation method, and pharmaceutical composition comprising the same | |
| SG11201808540SA (en) | Methods of treatment for cholestatic and fibrotic diseases | |
| SG11201809882XA (en) | Pharmaceutical combinations for treating cancer | |
| SG11201901850XA (en) | Dopamine-b-hydroxylase inhibitors | |
| SG11202000494UA (en) | Drug delivery composition | |
| SG11201901048VA (en) | Pharmaceutical compositions and uses directed to lysosomal storage disorders |